...
首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants.
【24h】

Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants.

机译:造血干细胞移植后小儿患者的静脉闭塞性疾病:活化凝血和纤溶标记物与天然抗凝剂的相关性。

获取原文
获取原文并翻译 | 示例
           

摘要

Prediction of veno-occlusive disease (VOD), its precise diagnosis, and treatment have been the subject of various studies, but still remain unclear. Our goal was to investigate the levels of activated coagulation and fibrinolysis markers and natural anticoagulants in pediatric patients with VOD after hematopoietic stem cell transplantation (HSCT). We investigated 47 pediatric patients: 20 with neuroblastoma, 17 with leukemias, and 10 with lymphomas and measured the values of antithrombin (AT), protein C (PC), fibrinogen (FI), thrombin AT complex, prothrombin fragments 1+2 (F1+2), and D-dimer from day -7 to day +30 post-HSCT. Patients were monitored for the occurrence of VOD, and it occurred in 10 patients at a median post-HSCT day of 17.5 (range: 2 to 28 d). In the VOD group, at baseline the levels of FI were significantly lower, and on days +7 and +14 a relevant difference existed in F1+2 levels. The levels of PC were significantly lower on day +14. Logistic multivariate regression analysis between the groups showed significantly different D-dimer levels on day +14. On day +30, the levels of PC, AT, and F1+2 were different between these 2 groups of patients. The levels of D-dimer and F1+2 were increased, and PC and FI decreased before the clinical onset of VOD. The parameter differences may have a predictive value in VOD onset, which makes them candidates to be routinely monitored in patients after HSCT.
机译:静脉阻塞性疾病(VOD)的预测,精确的诊断和治疗已成为各种研究的主题,但仍不清楚。我们的目标是调查造血干细胞移植(HSCT)后患儿VOD的小儿活化凝血和纤溶标记物以及天然抗凝剂的水平。我们调查了47名儿科患者:20例神经母细胞瘤,17例白血病和10例淋巴瘤,并测量了抗凝血酶(AT),蛋白C(PC),纤维蛋白原(FI),凝血酶AT复合物,凝血酶原片段1 + 2(F1 +2),以及从HSCT后的第-7天到+30天的D-二聚体。监测患者的VOD发生情况,在10例患者中,发生HSCT后的中位数为17.5天(范围:2至28 d)。在VOD组中,在基线时FI的水平明显降低,在+7和+14天,F1 + 2的水平存在相关差异。第14天的PC水平显着降低。两组之间的逻辑多元回归分析显示,第14天的D-二聚体水平显着不同。在第30天,这两组患者的PC,AT和F1 + 2含量不同。在VOD临床发作之前,D-二聚体和F1 + 2的水平升高,PC和FI降低。参数差异可能在VOD发作中具有预测价值,这使它们成为HSCT后患者常规监测的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号